Your browser doesn't support javascript.
loading
Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer.
Ma, Fei; Guan, Yanfang; Yi, Zongbi; Chang, Lianpeng; Li, Qiao; Chen, Shanshan; Zhu, Wenjie; Guan, Xiuwen; Li, Chunxiao; Qian, Haili; Xia, Xuefeng; Yang, Ling; Zhang, Jianjun; Husain, Hatim; Liao, Zhongxing; Futreal, Andrew; Huang, Jian; Yi, Xin; Xu, Binghe.
Affiliation
  • Ma F; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Guan Y; Geneplus-Beijing, Beijing, China.
  • Yi Z; Geneplus-Beijing Institute, Beijing, China.
  • Chang L; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Li Q; Geneplus-Beijing, Beijing, China.
  • Chen S; Geneplus-Beijing Institute, Beijing, China.
  • Zhu W; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Guan X; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Li C; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Qian H; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Xia X; State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Yang L; State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Zhang J; Houston Methodist Research Institute, Weill Cornell School of Medicine, Houston, TX.
  • Husain H; Geneplus-Beijing, Beijing, China.
  • Liao Z; Geneplus-Beijing Institute, Beijing, China.
  • Futreal A; Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Huang J; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Yi X; Moores Cancer Center, University of California San Diego, La Jolla, CA.
  • Xu B; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.
Int J Cancer ; 146(5): 1359-1368, 2020 03 01.
Article in En | MEDLINE | ID: mdl-31241775
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Biomarkers, Tumor / Circulating Tumor DNA Type of study: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Middle aged Language: En Journal: Int J Cancer Year: 2020 Type: Article Affiliation country: China
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Biomarkers, Tumor / Circulating Tumor DNA Type of study: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Middle aged Language: En Journal: Int J Cancer Year: 2020 Type: Article Affiliation country: China